A follow-up study of 25 patients with pancreatic cancer receiving gemcitabine and cisplatin and 21-h infusional 5-fluorouracil

Malignancy Spectrum Pub Date : 2025-08-20 DOI:10.1002/msp2.70013

Mozaffar Aznab, Arash Golpazir Sorkheh, Kiumars Eslsm Pia, Sayed Javad Hossini, Fatemeh Heydarpour

{"title":"A follow-up study of 25 patients with pancreatic cancer receiving gemcitabine and cisplatin and 21-h infusional 5-fluorouracil","authors":"Mozaffar Aznab, Arash Golpazir Sorkheh, Kiumars Eslsm Pia, Sayed Javad Hossini, Fatemeh Heydarpour","doi":"10.1002/msp2.70013","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine, cisplatin, and 21-h infusional 5-fluorouracil (5-FU).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study was a prospective, observational study at a medical center in Western Iran. The clinical and survival data from 25 patients treated with gemcitabine, cisplatin, and 21-h infusional 5-FU at our center were prospectively assessed. Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU (650 mg/m²) for 21 h on Days 1, 2, 3, and 4. Gemcitabine was administered at a dose of 1 g/m² on Days 1 and 8, and cisplatin was administered at a dose of 60 mg/m² on Day 1, with granulocyte colony-stimulating factor (G-CSF) support. Each cycle was repeated every 21 days for 5−6 cycles.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 25 patients with an age range of 39−73 years were studied. One out of the two patients with stage Ⅱ cancer survived for more than 43 months. Four out of the 14 patients with stage Ⅲ cancer survived for more than 15 months. Seventeen patients died, and eight subjects were alive at the end of the study. The mean and median of overall survival (OS) rates for the 25 patients were 20 and 12 months, respectively. The median progression-free survival (PFS) was 6 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>It seems that the triple therapy with gemcitabine, cisplatin, and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.</p>\n </section>\n </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"140-144"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70013","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malignancy Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/msp2.70013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine, cisplatin, and 21-h infusional 5-fluorouracil (5-FU).

Methods

This study was a prospective, observational study at a medical center in Western Iran. The clinical and survival data from 25 patients treated with gemcitabine, cisplatin, and 21-h infusional 5-FU at our center were prospectively assessed. Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU (650 mg/m²) for 21 h on Days 1, 2, 3, and 4. Gemcitabine was administered at a dose of 1 g/m² on Days 1 and 8, and cisplatin was administered at a dose of 60 mg/m² on Day 1, with granulocyte colony-stimulating factor (G-CSF) support. Each cycle was repeated every 21 days for 5−6 cycles.

Results

A total of 25 patients with an age range of 39−73 years were studied. One out of the two patients with stage Ⅱ cancer survived for more than 43 months. Four out of the 14 patients with stage Ⅲ cancer survived for more than 15 months. Seventeen patients died, and eight subjects were alive at the end of the study. The mean and median of overall survival (OS) rates for the 25 patients were 20 and 12 months, respectively. The median progression-free survival (PFS) was 6 months.

Conclusion

It seems that the triple therapy with gemcitabine, cisplatin, and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.

Abstract Image

查看原文本刊更多论文

25例接受吉西他滨、顺铂联合5-氟尿嘧啶21小时输注的胰腺癌患者的随访研究

目的评价吉西他滨、顺铂和5-氟尿嘧啶（5-FU） 21小时输注治疗的晚期胰腺癌患者的临床特征和生存期。方法：本研究是在伊朗西部某医学中心进行的前瞻性观察性研究。前瞻性评估本中心接受吉西他滨、顺铂和21小时5-FU输注治疗的25例患者的临床和生存数据。患者接受化疗，化疗周期为5-FU （650 mg/m²）连续输注21小时，分别于第1、2、3、4天。吉西他滨在第1天和第8天以1 g/m²的剂量给药，顺铂在第1天以60 mg/m²的剂量给药，并支持粒细胞集落刺激因子（g - csf）。每21天重复一个周期，共5 ~ 6个周期。结果共纳入25例患者，年龄39 ~ 73岁。两名Ⅱ期癌症患者中有一名存活了43个月以上。14名Ⅲ期癌症患者中有4名存活了15个月以上。研究结束时，17名患者死亡，8名受试者存活。25例患者的平均和中位总生存期（OS）分别为20个月和12个月。中位无进展生存期（PFS）为6个月。结论吉西他滨、顺铂和输注5-FU三联疗法对晚期胰腺癌患者的PFS和OS有显著的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Malignancy Spectrum

自引率

0.00%

发文量